Startups

Moonlight AI

Courroux, Jura, Switzerland

Moonlight AI develops computer-vision systems that analyze routine blood, bone-marrow and cytology images alongside molecular/genomic data to support identification of cancer-related genomic biomarkers and prioritize diagnostic testing. Its Swiss platform targets hematological and solid-tumor workflows, including myelodysplastic syndromes, chronic lymphocytic leukemia and non-small-cell lung cancer. The company is pursuing regulatory approval and commercial deployment; published performance statements are developer claims, not independently established clinical clearance. Current public leaders are cofounders Christian Ruiz (CEO/CSO), Nicole H. Romano (CTO) and Stefan Habringer (CMO). The business began in2022 as Moonlight AI Sàrl, CHE-223.971.358, later Moonlight Operations AI Sàrl. Current holding/successor Moonlight AI SA (English AG), CHE-156.170.583, was registered April24,2026, received predecessor shares and a convertible claim as in-kind contributions, then absorbed the operations company in a merger published June29,2026. The statutory capital and exchanged shares are not new financing cash. Its May6,2026 announced closed seed round raised USD3.3M. It is distinct from The Moonlight Collective and MoonLake Immunotherapeutics.

Founded 2022

Team

Asmita DwivediBoard Member

Christian RuizChief Executive Officer / Chief Scientific Officer · Cofounder · Board Member

Ghazi Ben OthmanBoard Member

Kay Franz Horst BrunnerChairman of the Board

Nicole Halley RomanoChief Technology Officer · Cofounder · Board Member

Ruth Frances KetleyBoard Member

Sezai TaskinCofounder (published 2023) · Chief Executive Officer (historical, published 2023)

Stefan HabringerChief Medical Officer · Cofounder · Board Member

Investments

$3M2026-05-06	VP Venture Partners, Lotus One Investment Pte Ltd, MEDIN Fund Management, QAI Ventures, N & V Capital AG
$—2023-03-15	Kick Foundation

team@apexlogos.ai8 hours ago
Portrait verification update: KayFranzHorstBrunner authentic photograph retrieved from named current Alivion board https://alivion.ch/company and original https://alivion.ch/__l5e/assets-v1/3d05f7be-e6ac-411f-bc4e-1ba4d39a2da7/kay-brunner.png . Roche/Abbott career matches own KayStone and exact Swiss statutory identity. Earlier note describing unresolved photograph is superseded; excluded video still remains research-only.
team@apexlogos.ai8 hours ago
Funding and completeness qualifications: own May6,2026 closed seedUSD3.3M verified, individual allocations unpublished. QAI previously backed the company early, but earlier ticket/stage/date and whether rolled into current seed remain unresolved; no guessed200K accelerator check or extra priced round. Venture Kick March15,2023 awarded CHF10000 at its first stage; actual payment is not established, so the award event has NULL paid-cash total and full foundation-hosted grantor/programme profile is verified; KickFoundation10948 source-qualified award relationship85905 is recorded with paidcashNULL. University Basel Innovation Office also publicly describes a Propelling Grant, amount/day/payment unresolved; DayOne participation/support logos are not evidence of cash investments. Sources: https://www.venturekick.ch/Startups-revolutionizing-orthodontics-leveraging-AI-for-oncological-diagnostics-simplifiying-recruitment-making-hydrogen-production-sustainable-and-developing-an-immunebased-cancer-therapy-receive-CHF-10000-each ; https://www.linkedin.com/posts/innovation-unibas_funding-alert-moonlight-ai-raised-a-activity-7457799876513284098-RMsN . Current public leadership3 and statutory directors7 are complete after manager callbacks, including overlapping leaders. Historical2023 SezaiCEO/cofounder qualified separately. KayBrunner genuine portrait is verified on named own Alivion board page; the earlier own-site video still remains excluded. 2026 in-kind holding formation and merger are legal continuity, not cash financing.